Spyre Therapeutics, Inc. SYRE Change in Accrued Liabilities
Change in Accrued Liabilities at other companies
Other financials
Where this comes from
Reported directly by Spyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities.
The official record: Spyre Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Spyre Therapeutics, Inc.'s change in accrued liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Spyre Therapeutics, Inc.'s change in accrued liabilities?
- Spyre Therapeutics, Inc. (SYRE) reported change in accrued liabilities of $3.65M in Q1 2026.
- How has Spyre Therapeutics, Inc.'s change in accrued liabilities changed year-over-year?
- Spyre Therapeutics, Inc.'s change in accrued liabilities increased by 160.9% year-over-year, from -$6M to $3.65M.
- What does change in accrued liabilities mean?
- Change in accrued expenses and other current liabilities, reflecting timing differences between expense recognition and cash payment.